Share your videos with the world

What's The Secret To A Lasting Relationship? Going The Distance. Going The Distance with Match Affinity follows Mike & Alanna's epic journey in a motorbike and sidecar. They aim to answer the question, 'what's the secret to a lasting relationship'. On the way they meet hundreds of couples to find out what has made their relationship last. Join Mike and Alanna on the latest leg of this incredible journey to discover the secret to a lasting relationship in the UK.

Volvo Cars is teaming up with footballing icon Zlatan Ibrahimović again for the European launch campaign of the V90 premium estate in advance of the European Championships football tournament. The campaign will go live tonight on national TV stations and on Social Media platforms. The new campaign shows the former Paris Saint-Germain striker, a long-time Volvo driver and fan, looking back at his rise from humble beginnings in one of Sweden’s toughest neighbourhoods in Malmö to international sporting stardom. Zlatan, who is currently preparing for the European Championships feels a close affinity with the Swedish car brand. “I’m happy to be working with Volvo Cars again. I’ve seen the new cars, I’ve driven and tested them. And I think they’re fantastic. Just like me, Volvo has gone their own way and dared to think differently. The previous campaign we did was good, but this time it’s Made by Zlatan,” said Zlatan Ibrahimović. “The campaign is a celebration of the independent mind, of the power that lies in the ability to think differently. There are many similarities between Zlatan’s and Volvo’s journeys. We haven’t gotten to where we are now by doing the same as everyone else,” said Anders Gustafsson, Senior Vice President, Europe, Middle East and Africa at Volvo Car Group. To view the multimedia release go to: http://www.multivu.com/players/uk/7848551-volvo-cars-v90-campaign-zlatan-ibrahimovic/

http://www.mattejohansson.com/ ONE TAKE 100% Improvisation. It's not perfect, but it's more fun do play! If you like it, please feel free to

Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago. The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins. To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody